Search

Your search keyword '"Namenda (Medication) -- Product introduction"' showing total 7 results
Start Over Descriptor "Namenda (Medication) -- Product introduction"
7 results on '"Namenda (Medication) -- Product introduction"'

1. Forest Labs Faces Loss of Cash-Cow Drug

Author

Brown, Greg

Subjects
Standard & Poor's Corp. -- Product introduction, Cardiovascular agents -- Product introduction, Computer services industry -- Product introduction, Cattle -- Product introduction, Computer services industry, News, opinion and commentary, Lexapro (Medication) -- Product introduction, Namenda (Medication) -- Product introduction
Abstract

Byline: Greg Brown Forest Labs (FRX) is an interesting niche pharma stock with a strong drug pipeline. However, a cash-cow drug is leaving the fold for generic production, creating a [...]

Published
2012

2. Regulators take a growing interest in drug-makers' moves to protect profits

Author

Appleby, Julie

Subjects
Allergan PLC -- Cases -- Product introduction, Antitrust law -- Cases, Pharmaceutical industry -- Cases -- Product introduction, Company legal issue, Antitrust issue, Business, Computers and office automation industries, Telecommunications industry, Namenda (Medication) -- Product introduction
Abstract

Byline: Julie Appleby Executives at drug company Actavis knew they had to move fast to avoid a plunge in sales of their top-selling drug, Namenda, a treatment for Alzheimer's disease [...]

Published
2015

3. Panel backs memantine for moderate, severe Alzheimer's: FDA approval likely this year

Author

Mechcatie, Elizabeth

Subjects
Forest Laboratories Inc. -- Product introduction, Namenda (Medication) -- Product introduction, Pharmaceutical industry -- Product introduction, Alzheimer's disease -- Drug therapy
Abstract

BETHESDA, M D. -- By the end of this year, the first drug to treat moderate to severe Alzheimer's disease could be approved by the Food and Drug Administration. At [...]

Published
2003

4. Forest Announces U.S. Availability of New Once-Daily NAMENDA XR

Subjects
United States. Food and Drug Administration, Forest Laboratories Inc. -- Product introduction, Amyloid beta-protein, Drug approval, Alzheimer's disease -- Drug therapy, Pharmaceutical industry -- Product introduction, Business, Business, international, Namenda (Medication) -- Product introduction
Abstract

-- Treatment for moderate to severe Alzheimer's Disease is now available to patients in a convenient extended release formulation -- NEW YORK -- Forest Laboratories, Inc. announced today that NAMENDA [...]

Published
2013

5. Positive data for Namenda

Subjects
Forest Laboratories Inc. -- Management, Forest Laboratories Inc. -- Product introduction, Forest Laboratories Inc. -- Drug testing, Forest Laboratories Inc. -- Contracts, Cypress Bioscience Inc. -- Contracts, High technology industry -- Contracts, Pharmaceutical industry -- Management, Pharmaceutical industry -- Product introduction, Pharmaceutical industry -- Drug testing, Pharmaceutical industry -- Contracts, Contract agreement, Company business management, Business, Health care industry, Namenda (Medication) -- Drug testing, Namenda (Medication) -- Product introduction
Abstract

Gregory Gilbert First vice president Merrill Lynch Stock: Forest Labs Rating: Neutral Volatility risk: High Forest announced results (Jan. 7) from two Phase III trials for Namenda used as monotherapy [...]

Published
2004

6. New drug approved for Alzheimer's

Subjects
Forest Laboratories Inc. -- Product introduction, Forest Laboratories Inc. -- Licensing, certification and accreditation, Pharmaceutical industry -- Licensing, certification and accreditation, Pharmaceutical industry -- Product introduction, Alzheimer's disease -- Drug therapy, Alzheimer's disease -- Licensing, certification and accreditation, Alzheimer's disease -- Product introduction, Business, Pharmaceuticals and cosmetics industries, Retail industry, Namenda (Medication) -- Product introduction, Namenda (Medication) -- Licensing, certification and accreditation
Abstract

The Food and Drug Administration has approved memantine for treating moderate to severe Alzheimer's disease. Forest Laboratories Inc. is marketing the product under the Namenda name. Separately, Janssen Pharmaceutical Products [...]

Published
2003

7. Merz' Namenda performs well in USA

Subjects
Merz Pharmaceuticals -- Product introduction, Pharmaceutical industry -- Product introduction, Alzheimer's disease -- Care and treatment, Pharmaceuticals and cosmetics industries, Namenda (Medication) -- Product introduction
Abstract

Frankfurt, Germany-headquartered Merz Pharma has reported the success of Namenda (memantine) following its US launch early this year (see also Marketletter January 19 and page 26 this issue) for the [...]

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results